semaglutide and cardiovascular outcomes in patients with type 2 diabetes Series: outcome trials for drugs SUSTAIN-6 Semaglutide cardiovascular outcomes align more

Direct-to-consumer health and wellness company Ro launched an online GLP-1 supply tracker as an interactive tool to give patients real-time insights on GLP-1 drug shortages

Outcomes form the STEER real-world study have revealed that semaglutide 2.4 mg had 57% greater risk reduction for heart attack, stroke and cardiovascular-related death or death from any cause, in people with overweight or obesity and CVD, who did not have any gaps in their treatment lasting more than 30 days, compared with tirzepatide

A Wegovy

Easy to download and print

Implications GLP-1RAs represent a novel, multifaceted therapeutic option in PsD, targeting both metabolic and inflammatory components